Cite
HARVARD Citation
Margonis, G. et al. (2016). Activating KRAS mutation is prognostic only among patients who receive preoperative chemotherapy before resection of colorectal liver metastases. Journal of surgical oncology. 114 (3), pp. 361-367. [Online].